Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
Date:11/14/2012

in the number of Satisfying Sexual Events (SSEs) and also showed clinically meaningful and statistically significant improved measures of overall sexual functioning and distress related to sexual dysfunction, compared to placebo.  Bremelanotide was well-tolerated during the trial.  The most common types of treatment-emergent adverse events reported more frequently in the bremelanotide arms were facial flushing, nausea and emesis, which were mainly mild-to-moderate in severity.  Adverse events that most commonly led to discontinuation were nausea and emesis.  No serious adverse events were attributable to bremelanotide during the trial.  Based on the results of discussions with the U.S. Food and Drug Administration (FDA) and external advisors regarding the results of this trial and further development steps, Phase 3 activities are anticipated to start in the second-half of calendar year 2013.

First Quarter Fiscal 2013 Financial Results
Palatin reported a net loss of $10.5 million, or $(0.15) per basic and diluted share, for the quarter ended September 30, 2012, compared to a net loss of $3.4 million, or $(0.10) per basic and diluted share, for the same period in 2011.

The increase in net loss for the quarter ended September 30, 2012, compared to the same period last fiscal year, was mainly attributable to a non-cash, non-operating expense of $7.1 million, which represented the increase in fair value of the warrants, which were previously liability classified until our increase in our authorized shares.Costs and Expenses
Total operating expenses were $3.4 million for the quarter ended September 30, 2012 and September 30, 2011.  Operating expenses consist of $1.1 million of general and administrative expenses and $2.3 million of research and development for the quarter ended September 30, 2012 and 2011.  General and administrative expenses consist mainly of compensation and related costs and research and developme
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... electronic age rests on our ability to control how ... through circuitry. Doing so requires particular precision, for applications ... that task falls to semiconductors. Now, a research ... and Applied Science and Arts and Sciences has shown ...
... April 8, 2011 VIGILAIR Systems, an ... instrumental in a newly published, and first of its ... patient Hospital Acquired Infections (HAI) with the application of ... Unit (NICU). The published article , Effect ...
... Calif., April 8, 2011 On April 12, at the ... and CEO of Marrone Bio Innovations (MBI), will ... an industry panel debating the topic of ,Feeding a Growing ... to curb environmental impact while producing enough food to feed ...
Cached Biology Technology:Penn research advances understanding of lead selenide nanowires 2Penn research advances understanding of lead selenide nanowires 3Newly Published Study Shows Dramatic Reduction in Hospital Acquired Infections 2Pam Marrone to Speak at Ag 2.0 Conference 2
(Date:7/9/2014)... Indiana state parks have helped restore the health of ... populations of white-tailed deer, a Purdue study shows. , ... of forest ecology, found that a 17-year-long Indiana Department ... parks has successfully spurred the regrowth of native tree ... , Jenkins said that while hunting may be ...
(Date:7/9/2014)... refers to species, selection for traits that are attractive ... selection enhances opportunities to mate, the tail of male ... University of California, Riverside have now found that sexual ... are linked. Describing the life histories of more ... the researchers found that species with placentas tend to ...
(Date:7/9/2014)... Rochelle, NY, July 9, 2014Biofuels derived from the oils ... to fossil fuels. To achieve this goal, optimization of ... in open pond systems, is needed. Sapphire Energy has ... of open pond algae cultivation systems, described in ... Liebert, Inc., publishers. The article is available on the ...
Breaking Biology News(10 mins):Hunting gives deer-damaged forests in state parks a shot at recovery 2Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Controlling contamination in open algae ponds for biofuels 2
... the helical, hairlike flagella that extend from their unicellular bodies. ... coli ) living in the human gut, have multiple flagella ... These cells turn somewhat acrobatically by unbundling their flagella, causing ... direction. But many microbes, including 90 percent of motile ...
... helped boost green foliage across the world,s arid regions ... CO2 fertilisation, according to CSIRO research., In findings based ... National University (ANU), found that this CO2 fertilisation correlated ... from 1982-2010 across parts of the arid areas studied ...
... donation is now one of the major reasons why ... trend may circumvent regulations at home or raise concerns ... the most controversial. Yet little is known about the ... - their characteristics, their motivation and their compensation. ...
Cached Biology News:Buckling up to turn 2Buckling up to turn 3Buckling up to turn 4Deserts 'greening' from rising CO2 2Egg donation in European clinics: Why do women do it? 2Egg donation in European clinics: Why do women do it? 3
... Analyzer for superior sensitivity, mass accuracy, and resolving power., Specifications:, ... ion selection range: 150 - 4000 m/z, * Resolution: 14,000 (1400 ... * Dynamic range: 4 orders of magnitude ... ...
... M (OSM) is a pleiotropic cytokine produced ... sarcoma cells. OSM inhibits the growth of ... fibroblast, smooth muscle and Kaposis sarcoma cell ... low density lipoprotein receptor expression on hepatoma ...
... trinor Prostaglandin F2α isopropyl ester (15(R)-17-phenyl ... latanoprost-related isomer containing both a double ... (β) hydroxyl group at C-15. Similar ... ester is a potential impurity in ...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
Biology Products: